Pharmaceutical Contract Manufacturing and Contract Market Size, Share, Growth, and Industry Analysis, By Type ( Big Pharma,Small & Mid-size Pharma,Generic Pharmaceutical Companies ), Regional Insights and Forecast to 2035

Pharmaceutical Contract Manufacturing and Contract Market Overview

The global Pharmaceutical Contract Manufacturing and Contract Market is forecast to expand from USD 133191.54 million in 2026 to USD 148348.74 million in 2027, and is expected to reach USD 351259.91 million by 2035, growing at a CAGR of 11.38% over the forecast period.

The global pharmaceutical contract manufacturing and contract market is an integral part of the life sciences supply chain, enabling over 63% of pharmaceutical companies worldwide to outsource production and research functions. In 2024, approximately 1,400 contract development and manufacturing organizations (CDMOs) were operational globally, providing formulation, packaging, and R&D services to biopharma firms. Biologic manufacturing outsourcing has expanded by 37% since 2021, while small-molecule contract manufacturing accounts for 52% of total outsourced pharmaceutical output. Regulatory-compliant facilities represent 74% of the total active CDMO sites, illustrating the sector’s growing emphasis on quality and standardization. As highlighted in the Pharmaceutical Contract Manufacturing and Contract Market Report, outsourcing now supports over 45% of new drug launches globally, driven by the need for scalability and cost efficiency.

In the United States, the pharmaceutical contract manufacturing and contract market accounts for 28% of global activity. The U.S. has over 320 FDA-approved CDMOs offering drug formulation, fill-finish, and analytical services. Biotech-focused outsourcing increased by 33% from 2022 to 2024, as startups sought external expertise for preclinical development. Approximately 62% of U.S. pharmaceutical companies outsource at least one manufacturing or testing stage. The demand for sterile injectables has increased contract production volume by 24% year-over-year. The U.S. government’s focus on domestic manufacturing resilience has led to a 19% rise in investments in GMP-certified facilities since 2023, making the country a global hub for advanced manufacturing partnerships.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising demand for biologics and biosimilars accounts for 46% of total outsourcing contracts in 2024, accelerating global production partnerships.
• Major Market Restraint: Regulatory compliance complexities impact 31% of CDMOs, causing delays in product release and increasing operational costs.
• Emerging Trends: Continuous manufacturing technologies have been adopted by 28% of CDMOs, improving efficiency and sustainability in pharmaceutical production.
• Regional Leadership: Asia-Pacific leads with 42% market share, followed by North America with 30%, Europe with 24%, and other regions holding 4%.
• Competitive Landscape: The top five global CDMOs represent 53% of global capacity, with specialization in biologics and sterile manufacturing segments.
• Market Segmentation: Manufacturing services dominate with 61% share, while research and development outsourcing accounts for 39% of global demand.
• Recent Development: Over 75 new contract manufacturing facilities were established worldwide between 2023 and 2025 to support global drug commercialization needs.

Pharmaceutical Contract Manufacturing and Contract Market Latest Trends

The Pharmaceutical Contract Manufacturing and Contract Market Trends reflect significant transformation driven by biotechnology, digitalization, and regulatory harmonization. Between 2023 and 2025, demand for large-molecule production outsourcing increased by 41%, primarily in monoclonal antibodies and recombinant proteins. Contract manufacturing organizations (CMOs) specializing in cell and gene therapies grew by 36%, reflecting rapid biopharma diversification. Single-use bioreactor implementation expanded by 29%, enhancing operational flexibility and reducing contamination risks. Artificial intelligence-enabled quality control systems were adopted by 27% of facilities to optimize batch release times. Additionally, continuous manufacturing and modular production units now account for 32% of newly constructed CDMO sites.

Digitalization of pharmaceutical R&D and supply chain processes also surged. Over 52% of CROs now utilize cloud-based clinical data management systems. The global outsourcing of analytical and stability testing increased by 22%, driven by complex regulatory documentation requirements. The Pharmaceutical Contract Manufacturing and Contract Market Analysis indicates that hybrid outsourcing models—combining both manufacturing and R&D partnerships—are growing steadily, representing 18% of total contracts in 2024. Sustainability initiatives have gained momentum, with 35% of CDMOs integrating green chemistry principles to reduce waste and energy use across production cycles.

Pharmaceutical Contract Manufacturing and Contract Market Dynamics

DRIVER

"Rising demand for complex biologics and specialty drugs."

The main driver fueling the Pharmaceutical Contract Manufacturing and Contract Market Growth is the surge in biologics and specialty pharmaceutical production. Biologics now represent 38% of the global pharmaceutical pipeline, with over 1,200 biologic candidates in various stages of clinical trials. Around 54% of biotech companies outsource development or manufacturing to CDMOs due to high infrastructure costs. The expansion of personalized medicine has resulted in a 33% increase in the demand for customized manufacturing solutions. Injectable formulations and sterile biologics now account for 46% of outsourced production volume. Contract service providers have expanded bioreactor capacity by 28% since 2022 to meet demand for high-potency APIs and cell-based therapies.

RESTRAINT

"Stringent regulatory and quality compliance challenges."

A major restraint in the Pharmaceutical Contract Manufacturing and Contract Industry Analysis is the complexity of regulatory oversight. Around 31% of CDMOs face compliance delays due to evolving GMP and validation protocols. Global regulators have conducted over 1,700 inspections across 2023–2024, identifying quality-related nonconformities in 14% of audited facilities. The rising cost of maintaining multi-region certifications has increased operational expenditure by 19% for small and mid-sized contract organizations. In addition, inconsistent documentation standards between the U.S. FDA, EMA, and PMDA affect approximately 22% of cross-border contract agreements, slowing product release and approvals.

OPPORTUNITY

"Expansion of biosimilars and vaccine manufacturing."

The growing biosimilar pipeline presents one of the largest opportunities in the Pharmaceutical Contract Manufacturing and Contract Market Forecast. More than 150 biosimilar candidates are currently in late-stage development worldwide. Vaccine outsourcing volumes grew by 47% between 2022 and 2024 as global healthcare systems expanded immunization programs. Over 65% of vaccine developers collaborate with CDMOs for fill-finish, formulation, and cold chain logistics. Furthermore, demand for mRNA-based vaccines and therapies led to 22 new production facilities constructed globally since 2023. The Pharmaceutical Contract Manufacturing and Contract Market Opportunities analysis suggests that partnerships in biologics and vaccine platforms will remain a primary growth driver in coming years.

CHALLENGE

"Workforce shortages and supply chain constraints."

The shortage of skilled pharmaceutical manufacturing professionals poses a significant challenge to the industry. Around 39% of CDMOs report talent shortages in process engineering and quality control roles. The average hiring time for technical positions increased by 21% in 2024. Supply chain disruptions have also impacted the availability of critical raw materials, delaying production schedules in 27% of facilities. Lead times for specialized excipients and bioreactor components increased by 25%, creating operational bottlenecks. To mitigate these challenges, CDMOs are investing 18% more annually in workforce training and digital supply chain systems.

Pharmaceutical Contract Manufacturing and Contract Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Manufacturing Services (CMO): Manufacturing services account for 61% of total market share, with over 900 global CMOs providing formulation, packaging, and production. Biologic manufacturing comprises 42% of all outsourced CMO projects, while small-molecule production represents 58%. The use of advanced technologies such as lyophilization and high-containment facilities increased by 33% since 2023. Approximately 26% of CMOs now offer end-to-end solutions, covering preformulation to commercial manufacturing. Continuous production lines have reduced lead times by 19%, significantly boosting manufacturing efficiency.

Research Services (CRO): Research services represent 39% of market share and include clinical trial management, bioanalytics, and pharmacovigilance. There are currently over 1,000 active CROs worldwide managing pharmaceutical and biotech R&D programs. Clinical trial outsourcing rose by 28% between 2023 and 2025. Data management automation has reduced trial durations by 17% on average. Over 45% of CROs are integrating predictive analytics to enhance study design accuracy. The Pharmaceutical Contract Manufacturing and Contract Market Report notes that CROs specializing in oncology and immunotherapy research account for 35% of outsourcing demand.

By Application

Big Pharma: Large pharmaceutical companies contribute 49% of total outsourcing demand. Over 70% of top-20 global pharma firms rely on external CMOs for secondary manufacturing and packaging. Strategic partnerships with long-term contracts increased by 31% between 2023 and 2025. Biologic drug outsourcing within Big Pharma expanded by 27% due to pipeline diversification. Multi-year service contracts now cover 56% of total outsourcing engagements.

Small & Mid-size Pharma: Small and mid-size firms represent 37% of contract manufacturing and research outsourcing volume. These companies outsource approximately 68% of clinical development activities to manage operational costs. Biotech startups have grown by 33% since 2022, driving demand for contract manufacturing partnerships. Around 22% of these firms use hybrid CDMO-CRO models for end-to-end development.

Generic Pharmaceutical Companies: Generic producers account for 14% of global outsourcing, focusing on cost efficiency and rapid market entry. Over 240 generic firms contracted manufacturing partnerships for oral solid dosage forms in 2024. Process optimization improved time-to-market by 18%. Quality assurance outsourcing increased by 23%, reflecting regulatory pressure on consistency.

Pharmaceutical Contract Manufacturing and Contract Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America represents 30% of global market share, with over 400 active CDMOs and CROs. The U.S. leads regional operations, while Canada contributes 11% to North America’s capacity. Over 57% of regional outsourcing involves biologics, particularly monoclonal antibodies and mRNA vaccines. Investments in sterile fill-finish facilities increased by 26% since 2023. The region has over 90,000 employees in contract manufacturing roles. Regulatory compliance excellence and digital automation have improved productivity by 21%. The Pharmaceutical Contract Manufacturing and Contract Market Outlook emphasizes growing partnerships between U.S.-based pharma and regional CMOs to strengthen domestic supply resilience.

Europe

Europe holds 24% of market share, with Germany, Switzerland, and Ireland being leading hubs. The region operates over 380 GMP-certified facilities, contributing to 46% of global contract API production. Biologic outsourcing in Europe rose by 29% between 2023 and 2025. The EU’s focus on quality compliance resulted in a 34% increase in technology transfer agreements. Around 19% of European CDMOs specialize in cell and gene therapy manufacturing. The Pharmaceutical Contract Manufacturing and Contract Industry Report identifies Europe as a leader in advanced aseptic processing and cold-chain capabilities, essential for biologic drug delivery.

Asia-Pacific

Asia-Pacific dominates with 42% of total global share, driven by cost-efficient manufacturing and infrastructure expansion. China, India, and South Korea account for 82% of regional output. India alone hosts over 270 USFDA-approved facilities, representing 40% of the world’s generic drug supply. Biologic manufacturing investments across China grew by 37% from 2023 to 2025. Over 60,000 professionals are employed in CDMO operations region-wide. Contract production of small molecules increased by 28%, and export-oriented projects make up 64% of Asia-Pacific outsourcing activity.

Middle East & Africa

The Middle East & Africa region accounts for 4% of global share but is growing due to government-led initiatives. The UAE and Saudi Arabia represent 63% of regional outsourcing capacity. Around 40 manufacturing facilities operate in this geography, with 22% focused on biologics. South Africa remains the continent’s largest player, managing 31% of Africa’s contract production. Government incentives have increased GMP certification rates by 26% in the last two years.

List of Top Pharmaceutical Contract Manufacturing and Contract Companies

• AbbVie
• Patheon
• Baxter Pharmaceutical Solutions LLC
• Grifols International, S.A.
• Lonza AG
• PPD
• Catalent
• Dalton Pharma Services

Top Companies with Highest Market Share

• Lonza AG holds approximately 11% of global market share, operating 35 large-scale production sites and serving over 250 biopharma clients worldwide.
• Catalent ranks second with 9% share, producing 90 billion+ doses annually across 50 facilities, and managing 1,400 active projects globally.

Investment Analysis and Opportunities

Global investments in pharmaceutical contract manufacturing increased by 39% between 2023 and 2025. Over $25 billion equivalent was directed into biologics, sterile injectables, and continuous manufacturing facilities. The Asia-Pacific region captured 46% of these investments, while North America received 33%. Over 80 new GMP-certified facilities became operational in 2024 alone. Around 28% of total investment targeted technology transfer and capacity expansion for advanced therapies. The Pharmaceutical Contract Manufacturing and Contract Market Opportunities emphasize emerging prospects in gene therapy, biosimilars, and mRNA-based drug production. CDMOs are investing 25% of annual capital in digital process automation and AI-driven quality assurance systems.

New Product Development

Innovation in the Pharmaceutical Contract Manufacturing and Contract Market is reshaping production efficiency and scalability. Between 2023 and 2025, over 65 new production platforms were launched worldwide. Single-use bioreactors with capacities above 2,000 liters saw 31% higher adoption rates. Modular cleanroom systems improved installation speed by 24%. New microreactor technologies increased small-scale drug synthesis yield by 18%. PPD and Catalent introduced digital batch-record systems that reduced release times by 27%. The Pharmaceutical Contract Manufacturing and Contract Market Insights reveal that over 22% of CDMOs now use robotics for aseptic filling and inspection. Green chemistry and solvent recovery initiatives cut process waste by 34%, enhancing sustainability across the industry.

Five Recent Developments (2023–2025)

• Lonza AG expanded biologics production capacity by 30% through new Swiss and Singapore facilities.
• Catalent launched automated fill-finish lines, increasing output by 26%.
• Patheon opened a new continuous manufacturing unit capable of producing 100 million solid doses annually.
• Baxter developed lyophilized injectable systems reducing manufacturing time by 21%.
• Grifols completed a plasma fractionation expansion project, increasing global plasma processing capacity by 25%.

Report Coverage of Pharmaceutical Contract Manufacturing and Contract Market

The Pharmaceutical Contract Manufacturing and Contract Market Research Report provides comprehensive coverage of outsourcing dynamics across manufacturing and research functions. It examines over 1,400 global CDMOs and CROs, analyzing service portfolios, capacity expansions, and client segments. Data from 50+ countries and 300 key facilities is evaluated to identify operational efficiencies, partnership models, and technology trends. The report explores contract-based manufacturing across small molecules, biologics, and emerging therapies. It provides detailed segmentation by region, service type, and application, alongside insights into over 70 recent product innovations and 50 large-scale investments. This Pharmaceutical Contract Manufacturing and Contract Industry Report offers B2B stakeholders actionable intelligence for strategic decision-making, covering outsourcing partnerships, R&D alliances, and technology advancements driving the global pharmaceutical ecosystem.

Pharmaceutical Contract Manufacturing and Contract Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 133191.54 Million in 2026
Market Size Value By	USD 351259.91 Million by 2035
Growth Rate	CAGR of 11.38% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Manufacturing Services (CMO) Research Services (CRO) By Application : Big Pharma Small & Mid-size Pharma Generic Pharmaceutical Companies
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample